- Home
- NTIP vs NRSN Comparison
NTIP vs NRSN Comparison
Compare NTIP & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- NRSN
- Stock Information
- Founded
- NTIP 1990
- NRSN 2017
- Country
- NTIP United States
- NRSN Israel
- Employees
- NTIP N/A
- NRSN N/A
- Industry
- NTIP Multi-Sector Companies
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- NRSN Health Care
- Exchange
- NTIP Nasdaq
- NRSN Nasdaq
- Market Cap
- NTIP 32.0M
- NRSN 29.8M
- IPO Year
- NTIP 1998
- NRSN 2021
- Fundamental
- Price
- NTIP $1.43
- NRSN $1.10
- Analyst Decision
- NTIP
- NRSN Buy
- Analyst Count
- NTIP 0
- NRSN 2
- Target Price
- NTIP N/A
- NRSN $14.00
- AVG Volume (30 Days)
- NTIP 5.4K
- NRSN 302.0K
- Earning Date
- NTIP 11-06-2025
- NRSN 12-17-2025
- Dividend Yield
- NTIP 6.94%
- NRSN N/A
- EPS Growth
- NTIP N/A
- NRSN N/A
- EPS
- NTIP N/A
- NRSN N/A
- Revenue
- NTIP $150,000.00
- NRSN N/A
- Revenue This Year
- NTIP N/A
- NRSN N/A
- Revenue Next Year
- NTIP N/A
- NRSN N/A
- P/E Ratio
- NTIP N/A
- NRSN N/A
- Revenue Growth
- NTIP N/A
- NRSN N/A
- 52 Week Low
- NTIP $1.16
- NRSN $0.80
- 52 Week High
- NTIP $1.90
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- NTIP 48.24
- NRSN 52.19
- Support Level
- NTIP $1.42
- NRSN $0.89
- Resistance Level
- NTIP $1.48
- NRSN $1.28
- Average True Range (ATR)
- NTIP 0.05
- NRSN 0.10
- MACD
- NTIP -0.00
- NRSN 0.02
- Stochastic Oscillator
- NTIP 50.00
- NRSN 57.36
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.